Carla Grandori, MD, PhD, SEngine Precision Medicine
Christopher Kemp, PhD, Fred Hutchinson
The Inn at Ranchero Santa Fee
5951 Linea Del Cielo
Rancho Santa Fe, CA 92067
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
Two major roadblock to improve cancer patient outcome are 1) the shortage of available targeted agents and 2) lack of precision in assigning existing drugs to patients. Most cancer drug development efforts focus on a small number of genes that are commonly mutated in cancer such as activated oncogenes. While there are obvious benefits to focusing on such targets and their downstream signaling components, a broader approach to target discovery will almost certainly provide increased opportunities. There are currently only ~ 100 cancer genes being targeted in the clinic yet the human genome contains at least 22,000 coding genes. Cancers have many vulnerabilities beyond mutated genes, for example, synthetic and collateral lethal genes, developmental pathways, lineage dependencies and other non-oncogene addictions. While there is increasing interest in synthetic lethality, examples of clinical success remain limited. The purpose of this forum will be to highlight roadblocks to exploiting synthetic lethality for clinical benefit and strategies to overcome these.
Here, we use a relaxed definition of synthetic lethality to include lineage dependencies and non-oncogene addictions as well as the use of drug combinatorics (e.g. targeting multiple pathways simultaneously). This will insure the meeting achieves the broadest possible impact as these ideas are interrelated and complementary.
The meeting will generate workable solutions to two major issues:
|Cheryl Arrowsmith, PhD||University Health Network|
|Jonathan Baell, PhD||Monash University|
|Rene Bernards, PhD||Netherlands Cancer Institute|
|Andrew Biankin, MD||University of Glasgow|
|Charlie Boone, PhD||University of Toronto|
|Mathew Garnett, PhD||Wellcome Sanger Institute|
|Carla Grandori, MD, PhD||Sengine Precision Medicine|
|Chris Kemp, PhD||Fred Hutchinson Cancer Research Center|
|Razelle Kurzrock, MD||UC San Diego|
|Chris Lord, PhD||Institute of Cancer Research, London|
|Beverly Mock, PhD||National Institutes of Health|
|Diane Simeone, MD||NYU Langone Health|
|Paul Workman||The Institute of Cancer Research|
|Michael Yaffe, MD, PhD||MIT|
|Brooke Emerling, PhD||Sanford Burnham Prebys Medical Discovery Institute|
|Andrew Venteicher, MD, PhD||University of Minnesota|
|Mark Zimmerman||Dana-Farber Cancer Institute|
San Diego International Airport (SAN) is approximately 30 minutes from the meeting location.
International participants are welcome to arrive on Wednesday to minimize chances for missed or delayed connections.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.
For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!